| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 11 | 2021 | 2527 | 1.720 |
Why?
|
| Myelodysplastic Syndromes | 16 | 2022 | 2979 | 1.400 |
Why?
|
| Protein Kinase Inhibitors | 13 | 2021 | 4757 | 1.360 |
Why?
|
| Fusion Proteins, bcr-abl | 6 | 2020 | 1094 | 1.340 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 7 | 2022 | 801 | 1.230 |
Why?
|
| Dasatinib | 4 | 2019 | 862 | 1.200 |
Why?
|
| Leukemia, Myeloid, Chronic-Phase | 3 | 2019 | 505 | 1.110 |
Why?
|
| Leukemia, Myeloid, Acute | 23 | 2023 | 6915 | 1.100 |
Why?
|
| Bridged Bicyclo Compounds, Heterocyclic | 9 | 2021 | 923 | 1.010 |
Why?
|
| Sulfonamides | 10 | 2022 | 1823 | 0.770 |
Why?
|
| Leukemia, Myelomonocytic, Chronic | 6 | 2021 | 426 | 0.730 |
Why?
|
| Mutation | 16 | 2021 | 15179 | 0.690 |
Why?
|
| Benzothiazoles | 1 | 2019 | 94 | 0.660 |
Why?
|
| Pyrazoles | 4 | 2021 | 1471 | 0.650 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 16 | 2022 | 15862 | 0.640 |
Why?
|
| Leukemia, Biphenotypic, Acute | 1 | 2018 | 52 | 0.620 |
Why?
|
| Skin Ulcer | 1 | 2017 | 77 | 0.590 |
Why?
|
| Clonal Evolution | 1 | 2019 | 253 | 0.590 |
Why?
|
| Sarcoma, Myeloid | 1 | 2017 | 95 | 0.560 |
Why?
|
| Hematopoiesis | 1 | 2019 | 560 | 0.540 |
Why?
|
| Antineoplastic Agents | 8 | 2021 | 14289 | 0.530 |
Why?
|
| Phenylurea Compounds | 1 | 2019 | 580 | 0.530 |
Why?
|
| Cytarabine | 7 | 2023 | 1973 | 0.470 |
Why?
|
| Aged, 80 and over | 26 | 2023 | 29902 | 0.460 |
Why?
|
| Myeloproliferative Disorders | 2 | 2020 | 767 | 0.450 |
Why?
|
| Evidence-Based Medicine | 1 | 2018 | 1085 | 0.420 |
Why?
|
| Aged | 37 | 2023 | 70117 | 0.410 |
Why?
|
| Blast Crisis | 3 | 2020 | 557 | 0.400 |
Why?
|
| Anemia, Sideroblastic | 2 | 2021 | 58 | 0.380 |
Why?
|
| Pathology, Molecular | 1 | 2011 | 128 | 0.380 |
Why?
|
| Molecular Targeted Therapy | 2 | 2019 | 2330 | 0.370 |
Why?
|
| Thrombocytosis | 2 | 2021 | 121 | 0.370 |
Why?
|
| Myelodysplastic-Myeloproliferative Diseases | 2 | 2021 | 114 | 0.370 |
Why?
|
| Middle Aged | 39 | 2023 | 86204 | 0.370 |
Why?
|
| Janus Kinases | 1 | 2011 | 174 | 0.360 |
Why?
|
| Tandem Repeat Sequences | 2 | 2019 | 201 | 0.330 |
Why?
|
| Adult | 30 | 2023 | 77950 | 0.320 |
Why?
|
| Humans | 58 | 2023 | 261506 | 0.310 |
Why?
|
| Practice Guidelines as Topic | 1 | 2018 | 2403 | 0.310 |
Why?
|
| Prognosis | 13 | 2021 | 21713 | 0.300 |
Why?
|
| Male | 36 | 2023 | 123000 | 0.300 |
Why?
|
| Diagnostic Errors | 1 | 2011 | 509 | 0.290 |
Why?
|
| Leukemia, Promyelocytic, Acute | 2 | 2019 | 430 | 0.270 |
Why?
|
| Young Adult | 13 | 2023 | 21445 | 0.270 |
Why?
|
| Leukemia | 2 | 2011 | 1635 | 0.270 |
Why?
|
| Referral and Consultation | 1 | 2011 | 899 | 0.270 |
Why?
|
| Comorbidity | 4 | 2019 | 2352 | 0.260 |
Why?
|
| Treatment Outcome | 13 | 2022 | 32848 | 0.260 |
Why?
|
| Female | 35 | 2022 | 141928 | 0.250 |
Why?
|
| Neoplasm Proteins | 3 | 2021 | 3230 | 0.250 |
Why?
|
| Nitriles | 4 | 2021 | 906 | 0.240 |
Why?
|
| Consolidation Chemotherapy | 3 | 2020 | 155 | 0.240 |
Why?
|
| Biomarkers, Tumor | 3 | 2020 | 10331 | 0.240 |
Why?
|
| Daunorubicin | 2 | 2020 | 301 | 0.210 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2020 | 4938 | 0.210 |
Why?
|
| Disease-Free Survival | 8 | 2020 | 10001 | 0.210 |
Why?
|
| Transcriptome | 2 | 2021 | 1859 | 0.200 |
Why?
|
| Antimetabolites | 1 | 2021 | 69 | 0.200 |
Why?
|
| Imatinib Mesylate | 3 | 2019 | 1665 | 0.190 |
Why?
|
| Myelopoiesis | 1 | 2021 | 31 | 0.190 |
Why?
|
| Follow-Up Studies | 4 | 2019 | 14889 | 0.190 |
Why?
|
| Skin Neoplasms | 1 | 2017 | 4654 | 0.190 |
Why?
|
| Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative | 1 | 2021 | 118 | 0.190 |
Why?
|
| Drug Administration Schedule | 4 | 2020 | 3472 | 0.190 |
Why?
|
| Primary Myelofibrosis | 2 | 2021 | 831 | 0.190 |
Why?
|
| Combined Modality Therapy | 4 | 2020 | 8865 | 0.180 |
Why?
|
| Maintenance Chemotherapy | 1 | 2021 | 202 | 0.180 |
Why?
|
| Kaplan-Meier Estimate | 7 | 2021 | 6207 | 0.180 |
Why?
|
| Leukemia, Myelomonocytic, Juvenile | 1 | 2020 | 33 | 0.180 |
Why?
|
| Myelitis, Transverse | 1 | 2019 | 13 | 0.180 |
Why?
|
| Retrospective Studies | 15 | 2023 | 37905 | 0.180 |
Why?
|
| Interferon Type I | 1 | 2021 | 250 | 0.180 |
Why?
|
| Intervertebral Disc Degeneration | 1 | 2019 | 22 | 0.170 |
Why?
|
| Clinical Studies as Topic | 1 | 2019 | 19 | 0.170 |
Why?
|
| Survival Rate | 7 | 2020 | 12221 | 0.170 |
Why?
|
| Tumor Suppressor Protein p53 | 3 | 2023 | 3552 | 0.170 |
Why?
|
| Blood Component Transfusion | 1 | 2019 | 89 | 0.170 |
Why?
|
| Remission Induction | 6 | 2021 | 3569 | 0.170 |
Why?
|
| Optic Neuritis | 1 | 2019 | 41 | 0.170 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2023 | 482 | 0.170 |
Why?
|
| Azacitidine | 2 | 2022 | 1149 | 0.160 |
Why?
|
| Water-Electrolyte Imbalance | 1 | 2019 | 92 | 0.160 |
Why?
|
| Survival | 1 | 2018 | 177 | 0.160 |
Why?
|
| Li-Fraumeni Syndrome | 1 | 2019 | 158 | 0.150 |
Why?
|
| Models, Biological | 2 | 2020 | 3254 | 0.150 |
Why?
|
| Biomimetics | 1 | 2017 | 33 | 0.150 |
Why?
|
| Up-Regulation | 2 | 2021 | 2450 | 0.150 |
Why?
|
| Mycoses | 1 | 2021 | 386 | 0.150 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2019 | 503 | 0.150 |
Why?
|
| Adolescent | 11 | 2020 | 31252 | 0.150 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 6 | 2021 | 6550 | 0.150 |
Why?
|
| World Health Organization | 1 | 2018 | 316 | 0.140 |
Why?
|
| Artificial Intelligence | 1 | 2020 | 388 | 0.140 |
Why?
|
| Thrombocytopenia | 1 | 2021 | 846 | 0.140 |
Why?
|
| Bone Marrow | 3 | 2021 | 2358 | 0.140 |
Why?
|
| Drug Discovery | 1 | 2019 | 324 | 0.140 |
Why?
|
| Drug Resistance, Neoplasm | 3 | 2019 | 5178 | 0.140 |
Why?
|
| Core Binding Factor Alpha 2 Subunit | 1 | 2017 | 217 | 0.140 |
Why?
|
| Benzimidazoles | 1 | 2018 | 428 | 0.130 |
Why?
|
| Induction Chemotherapy | 4 | 2019 | 669 | 0.130 |
Why?
|
| Fatal Outcome | 1 | 2017 | 829 | 0.130 |
Why?
|
| Intubation, Intratracheal | 1 | 2019 | 445 | 0.120 |
Why?
|
| Lymphocyte Activation | 1 | 2019 | 1688 | 0.120 |
Why?
|
| Intensive Care Units | 1 | 2019 | 717 | 0.120 |
Why?
|
| Leukemia, Myeloid | 1 | 2019 | 941 | 0.120 |
Why?
|
| Clinical Trials as Topic | 2 | 2017 | 3719 | 0.120 |
Why?
|
| Gene Rearrangement | 1 | 2018 | 783 | 0.120 |
Why?
|
| Pyrimidines | 3 | 2020 | 3518 | 0.120 |
Why?
|
| Germ-Line Mutation | 1 | 2019 | 1046 | 0.120 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2021 | 2291 | 0.110 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2021 | 1248 | 0.110 |
Why?
|
| Alleles | 1 | 2019 | 2437 | 0.110 |
Why?
|
| Academic Medical Centers | 1 | 2016 | 672 | 0.110 |
Why?
|
| Translocation, Genetic | 1 | 2018 | 1245 | 0.110 |
Why?
|
| Vidarabine | 1 | 2017 | 1341 | 0.100 |
Why?
|
| Janus Kinase 2 | 1 | 2016 | 679 | 0.100 |
Why?
|
| Incidence | 3 | 2018 | 5673 | 0.100 |
Why?
|
| Biomarkers | 3 | 2020 | 5047 | 0.100 |
Why?
|
| Peptide Fragments | 1 | 2017 | 1271 | 0.100 |
Why?
|
| Pilot Projects | 1 | 2018 | 2803 | 0.100 |
Why?
|
| Neoplasms, Second Primary | 1 | 2020 | 1350 | 0.100 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2017 | 833 | 0.100 |
Why?
|
| Intracranial Hemorrhages | 1 | 2011 | 121 | 0.090 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2021 | 3251 | 0.090 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2023 | 2796 | 0.090 |
Why?
|
| Interprofessional Relations | 1 | 2011 | 213 | 0.090 |
Why?
|
| Cohort Studies | 4 | 2019 | 9244 | 0.090 |
Why?
|
| Biopsy | 1 | 2017 | 3443 | 0.090 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2017 | 2488 | 0.080 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2021 | 8873 | 0.080 |
Why?
|
| Hematologic Neoplasms | 1 | 2019 | 1870 | 0.070 |
Why?
|
| Idarubicin | 2 | 2019 | 446 | 0.070 |
Why?
|
| Cancer Care Facilities | 1 | 2011 | 884 | 0.070 |
Why?
|
| Risk | 2 | 2021 | 1972 | 0.070 |
Why?
|
| Signal Transduction | 2 | 2017 | 11965 | 0.070 |
Why?
|
| Proportional Hazards Models | 2 | 2014 | 4988 | 0.070 |
Why?
|
| Neoplasms | 3 | 2021 | 15193 | 0.070 |
Why?
|
| Serum Albumin | 2 | 2019 | 257 | 0.060 |
Why?
|
| L-Lactate Dehydrogenase | 2 | 2018 | 299 | 0.060 |
Why?
|
| Research Design | 1 | 2011 | 1544 | 0.060 |
Why?
|
| Multivariate Analysis | 1 | 2011 | 4298 | 0.060 |
Why?
|
| Asparaginase | 1 | 2023 | 184 | 0.060 |
Why?
|
| Risk Factors | 5 | 2020 | 17523 | 0.050 |
Why?
|
| Quality of Life | 1 | 2016 | 4532 | 0.050 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2020 | 10035 | 0.050 |
Why?
|
| Diagnosis, Differential | 1 | 2011 | 4744 | 0.050 |
Why?
|
| Myeloid Cell Leukemia Sequence 1 Protein | 1 | 2023 | 275 | 0.050 |
Why?
|
| Recurrence | 2 | 2020 | 4758 | 0.050 |
Why?
|
| Risk Assessment | 3 | 2021 | 6869 | 0.050 |
Why?
|
| Arthralgia | 1 | 2021 | 89 | 0.050 |
Why?
|
| Drug Evaluation | 1 | 2020 | 425 | 0.050 |
Why?
|
| Benzoates | 1 | 2021 | 136 | 0.050 |
Why?
|
| Acute Disease | 2 | 2019 | 2422 | 0.050 |
Why?
|
| Constipation | 1 | 2021 | 177 | 0.050 |
Why?
|
| IMP Dehydrogenase | 1 | 2020 | 27 | 0.050 |
Why?
|
| Algorithms | 1 | 2011 | 3890 | 0.050 |
Why?
|
| Receptor-Interacting Protein Serine-Threonine Kinases | 1 | 2019 | 39 | 0.050 |
Why?
|
| Polyethylene Glycols | 1 | 2023 | 615 | 0.050 |
Why?
|
| Hydrazines | 1 | 2021 | 208 | 0.040 |
Why?
|
| DNA Methylation | 2 | 2021 | 2669 | 0.040 |
Why?
|
| Staurosporine | 1 | 2019 | 143 | 0.040 |
Why?
|
| Drug Substitution | 1 | 2018 | 87 | 0.040 |
Why?
|
| Administration, Intravenous | 1 | 2019 | 249 | 0.040 |
Why?
|
| Withholding Treatment | 1 | 2019 | 161 | 0.040 |
Why?
|
| Febrile Neutropenia | 1 | 2018 | 65 | 0.040 |
Why?
|
| Receptors, Immunologic | 1 | 2020 | 309 | 0.040 |
Why?
|
| Neutropenia | 1 | 2022 | 968 | 0.040 |
Why?
|
| Antigens, CD34 | 1 | 2019 | 593 | 0.040 |
Why?
|
| Nuclear Proteins | 2 | 2020 | 3343 | 0.040 |
Why?
|
| Patient Transfer | 1 | 2019 | 137 | 0.040 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2020 | 665 | 0.040 |
Why?
|
| Propensity Score | 1 | 2020 | 750 | 0.040 |
Why?
|
| Platelet Count | 1 | 2018 | 490 | 0.040 |
Why?
|
| Pyridazines | 1 | 2020 | 293 | 0.040 |
Why?
|
| Leukocyte Count | 1 | 2018 | 684 | 0.040 |
Why?
|
| Europe | 1 | 2018 | 649 | 0.040 |
Why?
|
| Gene Frequency | 1 | 2020 | 1163 | 0.040 |
Why?
|
| Triazoles | 1 | 2021 | 617 | 0.040 |
Why?
|
| Tretinoin | 1 | 2019 | 623 | 0.040 |
Why?
|
| Proteomics | 1 | 2023 | 1380 | 0.030 |
Why?
|
| Protein Kinases | 1 | 2019 | 874 | 0.030 |
Why?
|
| Pneumonia | 1 | 2021 | 751 | 0.030 |
Why?
|
| Antifungal Agents | 1 | 2021 | 834 | 0.030 |
Why?
|
| Membrane Glycoproteins | 1 | 2020 | 1073 | 0.030 |
Why?
|
| Age Factors | 2 | 2017 | 5377 | 0.030 |
Why?
|
| Pedigree | 1 | 2019 | 1890 | 0.030 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2021 | 1048 | 0.030 |
Why?
|
| Imidazoles | 1 | 2020 | 999 | 0.030 |
Why?
|
| Pyridines | 1 | 2021 | 1244 | 0.030 |
Why?
|
| Animals | 1 | 2019 | 59536 | 0.030 |
Why?
|
| Hemorrhage | 1 | 2018 | 712 | 0.030 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2021 | 1756 | 0.030 |
Why?
|
| Endocrine System Diseases | 1 | 2014 | 83 | 0.030 |
Why?
|
| Gastrointestinal Diseases | 1 | 2018 | 589 | 0.030 |
Why?
|
| Survival Analysis | 2 | 2016 | 9180 | 0.030 |
Why?
|
| Transplantation, Homologous | 1 | 2019 | 2843 | 0.030 |
Why?
|
| DNA Mutational Analysis | 1 | 2018 | 2283 | 0.030 |
Why?
|
| Enzyme Inhibitors | 1 | 2020 | 1879 | 0.030 |
Why?
|
| Fatigue | 1 | 2018 | 1239 | 0.030 |
Why?
|
| Chromosome Aberrations | 1 | 2018 | 1960 | 0.020 |
Why?
|
| Salvage Therapy | 1 | 2019 | 2054 | 0.020 |
Why?
|
| Inflammation | 1 | 2019 | 2522 | 0.020 |
Why?
|
| Repressor Proteins | 1 | 2017 | 1664 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2014 | 2316 | 0.020 |
Why?
|
| Genomics | 1 | 2020 | 2738 | 0.020 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2021 | 2390 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2018 | 6009 | 0.020 |
Why?
|
| Disease Progression | 1 | 2019 | 6682 | 0.020 |
Why?
|
| Phenotype | 1 | 2019 | 6295 | 0.020 |
Why?
|
| Immunotherapy | 1 | 2020 | 3341 | 0.020 |
Why?
|
| Prevalence | 1 | 2014 | 3260 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2021 | 12873 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2014 | 4892 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2019 | 5539 | 0.020 |
Why?
|
| Time Factors | 1 | 2016 | 12926 | 0.010 |
Why?
|
| Cardiovascular Diseases | 1 | 2014 | 2195 | 0.010 |
Why?
|